Epirus Biopharmaceuticals

About

Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.

Boston,Massachusetts,United States
51 - 100

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $36M
Industries: Biotechnology,Life Science,Therapeutics
Founded date: Mar 28, 2000
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:EPRSQ

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

5

$83.08M

Epirus Biopharmaceuticals has raised a total of $83.08M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2014 from a IPO round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jul 15, 2014	IPO	—	—	—	—	Detail
Apr 16, 2014	Series B	$36M	8	Livzon Mabpharm	—	Detail
Jul 1, 2012	Series Unknown	$5M	2	—	—	Detail
Apr 1, 2012	Series Unknown	$8.08M	2	—	—	Detail
Jan 1, 2011	Series A	$34M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

1

0

Epirus Biopharmaceuticals has made 1 investments. Their most recent investment was on Dec 7, 2022, when Maergo raised $20M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Dec 7, 2022 Maergo	Seed	$20M	E-Commerce	—

Investors

Number of Lead Investors

Number of Investors

1

8

Epirus Biopharmaceuticals is funded by 8 investors. Livzon Mabpharm and 5AM Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
Livzon Mabpharm	Yes	Series B
5AM Ventures	—	Series B
Adage Capital Management	—	Series B
Gibralt Capital Corporation	—	Series B
Greenwoods Investment	—	Series B
Montreux Equity Partners	—	Series B
Mousse Partners	—	Series B
TPG Biotech	—	Series B